On 5 August, the US Food and Drug Administration (FDA) granted approval to Moderna’s mRNA-based flu vaccine, mFLUSIVA, for adults aged 50–64, and accelerated approval for adults 65 and older. Moderna ...

The U.S. Food and Drug Administration (FDA) has approved the first flu vaccine built on messenger RNA (mRNA) technology, months after the agency refused to even consider the application. The shot, ...

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing ...

YOUNGSTOWN, Ohio (WKBN) — The FDA has approved a new flu vaccine for adults 50 and older. It's the first mRNA-based flu vaccine. It's expected to roll out this fall but may not be ready for the masses ...

After several disastrous flu seasons, there is some good news: The U.S. Food and Drug Administration approved a new, more effective flu vaccine for older adults that should be available in time for ...

The Food and Drug Administration just approved the new type of flu vaccine for adults ages 50 and older. It relies on the ...

Moderna’s mFLUSIVA is the first mRNA vaccine approved for seasonal flu. Its route to approval was unusual, with the FDA ...

Millions of older Americans will have access to a new type of influenza vaccine after the Food and Drug Administration ...

RNA technology is moving beyond vaccines to enable targeted gene-editing therapies and novel treatments for complex diseases, ...

Although experts estimate COVID vaccines saved more than three million American lives, a survey found only 56% of Americans ...

Vaccine makers can produce mRNA shots faster than those made with older technology, which could cut the risk of a mismatch ...